Quantcast

Latest Regenerative medicine Stories

2014-06-02 08:31:56

SACRAMENTO, Calif., June 2, 2014 /PRNewswire/ -- SynGen Inc., a company focused on the development and commercialization of instrument systems that harvest stem and progenitor cells from umbilical cord blood, bone marrow, peripheral blood, and cell culture, announced today that Dr. William Gerber has been appointed CEO to replace co-founder and lead inventor Philip Coelho. Mr. Coelho, who will become the Chief Technical Officer (CTO) of SynGen, noted "Bud Barry, my business partner and...

2014-06-02 08:29:08

On August 1, 2013 The Company issued 75,000,000 million shares as part of a venture to open restaurants in association with South Of The Border Holdings, Inc.; 70 Million have been canceled and returned to the company treasury. SARASOTA, Fla., June ­­2, 2014 /PRNewswire/ -- Caribbean International Holdings (OTC: CIHN) announced today that 70 million of the 75 million shares issued by the Company as part of a venture in association with South Of The Border Holdings, has been...

2014-05-30 16:24:52

SARASOTA, Fla., May 30, 2014 /PRNewswire-iReach/ -- On Friday, April 18(th) PGFX Patent Holdings, operating as Heritage Biosciences, LLC made an asset acquisition of proprietary methods, devices and intellectual property from Orogen Biosciences, Inc. Orogen, based out of Sarasota, Florida, was an early innovator in processing platelet rich plasma (PRP) and concentrating growth factors, cytokines, proteins and adhesion molecules to optimize the most effective and efficient methods for...

2014-05-29 08:30:21

SAN DIEGO, May 29, 2014 /PRNewswire/ -- ViaCyte, Inc., a regenerative medicine company focused on developing a cell replacement therapy for the treatment of patients with insulin-dependent diabetes, announced today that the Company has settled a patent dispute involving certain of the Company's definitive endoderm patents and patent applications. The dispute involved an appeal to the U.S. District Court by Asterias Biotherapeutics, Inc., (as assignee of Geron Corporation), which...

2014-05-22 23:09:01

Patients now have the opportunity to receive Regenerative Medicine services at Healthpointe. La Mirada, CA (PRWEB) May 22, 2014 Healthpointe Medical Group is proud to announce that they are offering Regenerative Medicine Services at their facilities located throughout Southern California. Regenerative Medicine is a rapidly growing field that is aimed at restoring and/or replenishing the normal function of tissues that are damaged or otherwise affected by diseases. Through this program,...

2014-05-16 08:27:03

/PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) CEO and President, Richard Garr, will present at the World Stem Cells & Regenerative Medicine Congress, on Thursday, May 22, at 11:35 a.m. BST in London, UK (http://www.terrapinn.com/conference/stem-cells/index.stm). Neuralstem is currently in a Phase II clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) with its NSI-566 stem cells and has been approved to commence a Phase I study in spinal cord...

2014-05-14 12:31:15

LONDON, May 14, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Biopreservation Market (Product Types - Equipment, LIMS, and Media; Applications - Regenerative Medicine, Biobanking, and Drug Discovery) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 -...

2014-05-13 12:34:16

NEW YORK, May 13, 2014 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels found in adipose tissue, announced today that Merril Hoge, former star NFL player and an on-air analyst for ESPN, has joined its Board of Advisors. According to Merril Hoge, "After tearing a ligament in my elbow I tried to rehab it to avoid...

2014-05-12 08:33:28

ROCKVILLE, Md., May 12, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months ended March 31, 2014 and provided a business and clinical update. "During the first quarter of 2014, we continued to advance the NSI-566 cell therapy platform through human clinical trials. We have completed treatment of the fourth cohort in our ALS Phase II escalating dose trials, in collaboration with our sites at University of Michigan, Emory and...

2014-05-12 08:33:04

SAN DIEGO, May 12, 2014 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced that the Company's Excellagen(®) flowable dermal matrix in combination with Orbsen Therapeutics' mesenchymal stromal stem cell therapy Cyndacel-M(TM) has been selected for clinical evaluation in a Phase 1b safety study for the potential treatment of chronic diabetic wounds to be funded by the European Union under EU Framework 7 (FP7). The project, known by the...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related